drugset / Trial / NCT04475198
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427
Phase 1
Terminated
24 enrolled
SiteOne Therapeutics, Inc.
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, double-blind, placebo controlled, study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. Subjects will be randomized to receive a single dose of ST-2427 or placebo in a Single Ascending Dose (SAD) design. A total of 30 subjects will be enrolled. Subjects will be randomized in a 4:2 ratio of ST-2427 to placebo. Study drug will be blinded to all subjects and investigators.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2021-08-18
- Completion
- 2021-08-18
Outcome
Outcome not reported
Stopped (Business): “strategic decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ST-2427 | Unknown | 5 mg | Intravenous |
| Subject | ST-2427 | Unknown | 10 mg | Intravenous |
| Subject | ST-2427 | Unknown | 15 mg | Intravenous |
| Subject | ST-2427 | Unknown | 22 mg | Intravenous |
| Subject | ST-2427 | Unknown | 33 mg | Intravenous |
Indications
No indication recorded.